Harwood Feffer LLP Announces Investigation of IPC The Medicines Company

NEW YORK, Feb. 12, 2014 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of The Medicines Company ("MDCO" or the "Company") (NASDAQ: MDCO), concerning whether the board has breached its fiduciary duties to shareholders.

(Logo: http://photos.prnewswire.com/prnh/20120215/MM54604LOGO )

On February 10, 2014 the FDA published a report stating that clinical trials for MDCO's drug candidate, Cangrelor, had been conducted unethically and inappropriately administered.  The report stated that the unethical conduct alone was basis for refusal of Cangrelor's new drug application. 

On February 12, 2014 trading of MDCO stock was halted pending a 7:30 a.m. meeting of the FDA's Cardiovascular and Renal Drugs Advisory Committee to discuss the Cangrelor application. 

Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.

If you own MDCO shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq.
Matthew M. Houston, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
                           (212)935-7400
Email:  bsachsmichaels@hfesq.com
Website:   http://www.hfesq.com

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. © 2013 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

SOURCE Harwood Feffer LLP